Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria ; Metabolic Unit, Institute of Biomedical Engineering, National Research Council (ISIB-CNR), Padua, Italy ; Mariahilf Community Pharmacy, Arnoldstein, Austria ; Medical Direction, Specialized Hospital Complex Agathenhof, Micheldorf, Austria.
PLoS One. 2013 Oct 16;8(10):e77326. doi: 10.1371/journal.pone.0077326. eCollection 2013.
Insulin-resistance is commonly found in adrenal incidentaloma (AI) patients. However, little is known about beta-cell secretion in AI, because comparisons are difficult, since beta-cell-function varies with altered insulin-sensitivity.
To retrospectively analyze beta-cell function in non-diabetic AI, compared to healthy controls (CON).
AI (n=217, 34%males, 57 ± 1 years, body-mass-index:27.7 ± 0.3 kg/m(2)) and CON [n = 25, 32%males, 56 ± 1 years, 26.7 ± 0.8 kg/m(2)] with comparable anthropometry (p ≥ 0.31) underwent oral-glucose-tolerance-tests (OGTTs) with glucose, insulin, and C-peptide measurements. 1mg-dexamethasone-suppression-tests were performed in AI. AI were divided according to post-dexamethasone-suppression-test cortisol-thresholds of 1.8 and 5 µg/dL into 3 subgroups: pDexa<1.8 µg/dL, pDexa1.8-5 µg/dL and pDexa>5 µg/dL. Using mathematical modeling, whole-body insulin-sensitivity [Clamp-like-Index (CLIX)], insulinogenic Index, Disposition Index, Adaptation Index, and hepatic insulin extraction were calculated.
CLIX was lower in AI combined (4.9 ± 0.2 mg · kg(-1) · min(-1)), pDexa<1.8 µg/dL (4.9 ± 0.3) and pDexa1.8-5 µg/dL (4.7 ± 0.3, p<0.04 vs.CON:6.7 ± 0.4). Insulinogenic and Disposition Indexes were 35%-97% higher in AI and each subgroup (p<0.008 vs.CON), whereas C-peptide-derived Adaptation Index, compensating for insulin-resistance, was comparable between AI, subgroups, and CON. Mathematical estimation of insulin-derived (insulinogenic and Disposition) Indexes from associations to insulin-sensitivity in CON revealed that AI-subgroups had ~19%-32% higher insulin-secretion than expectable. These insulin-secretion-index differences negatively (r=-0.45, p<0.001) correlated with hepatic insulin extraction, which was 13-16% lower in AI and subgroups (p<0.003 vs.CON).
AI-patients show insulin-resistance, but adequately adapted insulin secretion with higher insulin concentrations during an OGTT, because of decreased hepatic insulin extraction; this finding affects all AI-patients, regardless of dexamethasone-suppression-test outcome.
胰岛素抵抗在肾上腺意外瘤(AI)患者中很常见。然而,由于胰岛素敏感性的改变,β细胞功能的变化,因此关于 AI 中的β细胞分泌知之甚少,比较也很困难。
回顾性分析非糖尿病 AI 患者的β细胞功能,并与健康对照组(CON)进行比较。
AI(n=217,34%男性,57±1 岁,体重指数:27.7±0.3kg/m2)和 CON[n=25,32%男性,56±1 岁,26.7±0.8kg/m2]进行比较,两组患者的人体测量指标无显著差异(p≥0.31),均进行口服葡萄糖耐量试验(OGTT),检测血糖、胰岛素和 C 肽水平。AI 患者还进行了 1mg 地塞米松抑制试验(DST)。根据 DST 后皮质醇阈值 1.8 和 5μg/dL 将 AI 患者分为 3 组:pDexa<1.8μg/dL、pDexa1.8-5μg/dL 和 pDexa>5μg/dL。通过数学模型计算全身胰岛素敏感性[钳夹样指数(CLIX)]、胰岛素原指数、分布指数、适应指数和肝胰岛素提取率。
AI 患者的 CLIX 显著降低(4.9±0.2mg·kg-1·min-1),pDexa<1.8μg/dL(4.9±0.3)和 pDexa1.8-5μg/dL(4.7±0.3,p<0.04 与 CON:6.7±0.4)。AI 患者和各亚组的胰岛素原和分布指数均升高 35%-97%(p<0.008 与 CON),而 C 肽衍生的适应指数,补偿胰岛素抵抗,在 AI、亚组和 CON 之间无差异。从 CON 中与胰岛素敏感性相关的胰岛素(胰岛素原和分布)指数的数学估计表明,AI 亚组的胰岛素分泌水平比预期高 19%-32%。这些胰岛素分泌指数的差异与肝胰岛素提取率呈负相关(r=-0.45,p<0.001),AI 患者和亚组的肝胰岛素提取率分别降低 13-16%(p<0.003 与 CON)。
AI 患者表现出胰岛素抵抗,但在 OGTT 期间由于肝胰岛素提取减少,胰岛素分泌得到适当适应,胰岛素浓度升高;这一发现影响所有 AI 患者,与地塞米松抑制试验结果无关。